Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …

Introduction Upadacitinib is a Janus kinase inhibitor under investigation in patients with
psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in …

Purpose Tranexamic acid (TXA) reduces blood loss in patients undergoing total knee
arthroplasty (TKA). However, few studies have reported the optimum timing and dosage for …

Objective. To investigate the prevalence of psoriatic arthritis (PsA) in Japanese patients with
psoriasis. Methods. A multicenter, noninterventional, retrospective cross-sectional study was …

Synovitis-Acne-Pustulosis-Hyperostosis-Osteitis (SAPHO) syndrome is a rare inflammatory
osteoarticular disorder, which encompassed many diseases, including pustulotic arthro-…

Background: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment
of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment …

Background: Arthrodesis of the first metatarsophalangeal (MTP) joint has been recommended
for severe hallux valgus deformity in patients with rheumatoid arthritis (RA). However, with …

Objectives: Advances in drug therapy for rheumatoid arthritis (RA) have been encouraging
us to preserve the metatarsopharangeal (MTP) joint in correction of forefoot deformities, and …

Introduction This study aimed to investigate the current practice in the diagnosis and treatment
of SAPHO syndrome among the international rheumatology and dermatology communities…

Background Psoriasis is an immune-mediated skin disease for which the crosstalk between
genetic and environmental factors is responsible. To date, no definitive diagnostic criteria for …